Tag: Neovasc

Neovasc’s Management and Board of Directors Urge Shareholders to Vote In Favor of the Proposed Reverse Stock Split at the Upcoming Annual General and Special Meeting of Shareholders

VANCOUVER, May 15, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its management and board of directors (the “Board”) urge the Company’s shareholders of record to vote “FOR” the proposal authorizing the […]

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

VANCOUVER, May 10, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has received written notification (the “Nasdaq Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has […]

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

VANCOUVER, March 23, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX:NVCN) announced today that it has received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules […]

Neovasc to Present at LEERINK Partners 7th Annual Global Healthcare Conference

VANCOUVER, Feb. 12, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14th  at 2:30 pm ET at the Lotte New York Palace in New York City. A live […]

Neovasc Announces Receipt of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina

Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure NASDAQ, TSX: NVCN VANCOUVER, Feb. 1, 2018 /PRNewswire/ – Neovasc, Inc. (NVCN) (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies, today announced that the “Institut für das Entgeltsystem im […]

Neovasc Names Former BeneChill CEO as New Leader

VANCOUVER, Jan. 22, 2018 /PRNewswire/ – Neovasc (“Neovasc” or the “Company“) (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the “Board”) has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element […]

Neovasc Reducer Featured in Live Case at Berlin Symposium

VANCOUVER, Jan. 18, 2018 /PRNewswire/ – Neovasc Inc. today reported its Neovasc Reducer™ (“Reducer”) was featured in a “live case” broadcast to more than 800 participants at the Kardiologie Symposium 2018 held in Berlin, Germany. The successful live case was performed by Dr. Spyrantis and Professor Banai in the Sana-Klinikum Lichtenberg. “The […]

Neovasc Reports Tiara’s Clinical Case Load Accelerating

VANCOUVER, Jan. 8, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today provided an update on its clinical program for the Tiara™ (“Tiara”) valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation (“MR”), one of the most prevalent valvular heart diseases in western countries.  MR […]

Neovasc Inc. Receives NASDAQ Notification Regarding Minimum Bid Requirements

VANCOUVER, Jan. 2, 2018 /PRNewswire/ – Neovasc Inc. (NASDAQ, TSX:NVCN) announced today that it has received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on […]

Neovasc Reducer Featured in Live Case at ICI 2017

VANCOUVER, Dec. 6, 2017 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ (“Reducer”) medical device was featured in a “live case” broadcast at the 2017 Innovations in Cardiovascular Interventions (ICI) conference held in Tel Aviv, Israel.  In the live case broadcast to the conference from […]